🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Bravo à Emilie Gobeil de notre labo pour son article de vulgarisation scientifique sur son projet de maitrise. Maladie du foie gras : décoder nos gènes pour mieux la prévenir La Conversation Canada theconversation.com/maladie-du-foi…

Here is a summary of our latest CIHR funded work on NAFLD, just published in The Conversation Canada Uncovering the genetic causes of fatty liver disease — a growing health concern Emilie Gobeil theconversation.com/uncovering-the…

Je suis bien heureux de diffuser l’annonce de ce nouveau défi professionnel que je partagerai avec ma collègue Marie-Claude Vohl. Pour en connaitre plus sur les activités de la SQLNM, vous pouvez vous rentre sur le sqlnm.ca

Mon rêve de petite fille d’être juge à l’expo-sciences✅Très hâte de pouvoir écouter ces jeunes passionnés! Prochain rêve pour moi: Un jour, discuter avec Charles Tisseyre et participer à l’émission Découverte (C’était ma vision d’être scientifique plus jeune😅)

Elon Musk should buy 23andMe and release all GWAS summary statistics

Plusieurs bons points dans cette lettre, qui demande une hausse des bourses fédérales au doc & maîtrise. On pourrait ajouter qu'avec le plein emploi qui «sévit» présentement, ces bourses-là ont BEAUCOUP de compétition pour attirer les meilleurs talents. lesoleil.com/2022/05/15/les…

New paper: Mendelian Randomization Analysis Identifies Blood Tyrosine Levels as a Biomarker of Non-Alcoholic Fatty Liver Disease Very grateful to the Estonian Biobank's team for a great collaboration and to Emilie Gobeil for leading the project! mdpi.com/2218-1989/12/5…

The latest issue of Atherosclerosis (dedicated to Lp(a)) is out. Just in time for #EASCongress2022 I had the pleasure to contribute to review paper with Pia Kamstrup on Lp(a) and cardiovascular and valvular diseases from a genetic epidemiological perspective sciencedirect.com/science/articl…

I took the plane for the first time of my life few days ago to fall in love with the beauty of Milan🥰 Today, I will present for the first time in person my new results about the relationship between NAFLD and CAD #togetheratEAS2022

Hey #CardioTwitter, if you have 5 minutes to spare and would like to know what is Mendelian randomization and why is everyone in the field of preventive cardiology talking about it, then this short review is for you. #Mendel200 #EHJ academic.oup.com/eurheartj/adva…

L'édition du génome à l'aide des ciseaux moléculaires CRISPR/Cas9 pourrait-il éradiquer les maladies cardiovasculaires? La réponse de Benoit Arsenault chercheur à l'IUCPQ-ULaval, au micro de @MatthieuDugal bit.ly/3CFTbxv

Are you ready for us #AHA22 ? We are so grateful to have the opportunity to assist to this congress at Chicago🧬 Come see me, today 11am to 12pm at my poster (Zone 3 board SA3067)

Body fat distribution, fasting insulin levels and insulin secretion: A bidirectional Mendelian randomization study dlvr.it/SgFthX

We performed a large Mendelian randomization analysis to explore the effects of gut-related factors on several traits (body weight, lipids, insulin), diseases (CVD, NAFLD, T2D, AD, CKD, osteoporosis and depression) as well as parental lifespan 🥁 No meaningful effects were found

Le premier webinaire de la série "Les voies métaboliques", c'est mercredi prochain. Notre invité sera le Pr Benoit Lamarche, directeur du Centre NUTRISS de l'INAF et professeur à Université Laval Inscriptions 👉🏻 sqlnm.ca

New preprint from our lab: Drug target Mendelian randomization supports apolipoprotein C3-lowering for lipoprotein-lipid levels reductions and cardiovascular diseases prevention medrxiv.org/content/10.110…

📑The latest paper from our lab (led by Emilie Gobeil) is out now. Genetic inhibition of ANGPTL3, lipids, and cardiometabolic risk (European Society of Cardiology Journals) 👉🏻Lowering triglyceride levels may not systematically lead to reductions in coronary artery disease academic.oup.com/eurheartj/adva…

Highly recommend Rob Hegele's editorial: Inhibiting angiopoietin-like protein 3: clear skies or clouds on the horizon? "The benefit of targeting ANGPTL3 is clear in HoFH (...), but becomes cloudy when the clinical picture includes hypertriglyceridemia" academic.oup.com/eurheartj/adva…

This study by Benoit Arsenault and Eloi Gagnon provides evidence that apoC3 lowering could result in widespread benefits for cardiometabolic health and encourage the launch of trials on apoC3 inhibition for CAD prevention 🔗atherosclerosis-journal.com/article/S0021-… European Atherosclerosis Society Elsevier Cardiology